Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
Venus Concept Taps Endo’s Former CEO As New Chief Executive, Withdraws FY22 Guidance
Venus Concept Inc (NASDAQ:VERO) appointed Rajiv De Silva as the company’s CEO and board member, effective October 2. The company…